



(51) International Patent Classification:

C07D 487/10 (2006.01) A61K 31/497 (2006.01)
 C07D 487/08 (2006.01) A61K 31/444 (2006.01)
 C07D 487/04 (2006.01) A61K 31/438 (2006.01)
 C07D 471/10 (2006.01) A61K 31/407 (2006.01)
 C07D 471/08 (2006.01) A61P 11/00 (2006.01)
 C07D 401/14 (2006.01) A61P 29/00 (2006.01)
 C07D 401/12 (2006.01)

(21) International Application Number:

PCT/EP2020/070547

(22) International Filing Date:

21 July 2020 (21.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19187617.6 22 July 2019 (22.07.2019) EP

(71) Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(72) Inventors: KUTTRUFF, Christian, Andreas; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). BRETSCHNEIDER, Tom; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). GODBOUT, Cédric; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). KOOLMAN, Hannes, Fiepko; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). MARTYRES, Dominic; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE). ROTH, Gerald, Juer-gen; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(74) Agent: SIMON, Elke, Anna, Maria et al.; Boehringer Ingelheim International GmbH, Corporate Patents, Binger Strasse 173, 55216 INGELHEIM AM RHEIN (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: N-METHYL, N-(6-(METHOXY)PYRIDAZIN-3-YL) AMINE DERIVATIVES AS AUTOTAXIN (ATX) MODULATORS FOR THE TREATMENT OF INFLAMMATORY AIRWAY OR FIBROTIC DISEASES

(57) Abstract: The present invention relates to N-methyl, N-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators for the treatment of inflammatory airway or fibrotic diseases such as e.g. idiopathic lung disease (IFF) or systemic sclerosis (SSc). The present description discloses the preparation of exemplary compounds (e.g. pages 57 to 75; examples 1.1 to 5) as well as relevant biological data thereof (e.g. pages 15 to 21, tables 1 to 9). An exemplary compound is e.g. 1-(6-(4-(((6-(trifluoromethyl)pyridin-3-yl)methoxy)pyridazin-3-yl)amino)methyl)phenyl)-2,6-diazaspiro[3.3]heptan-2-yl)ethan-1-one (example 1.1).